Case Reports

Sweet Syndrome Induced by Oral Acetaminophen-Codeine Following Repair of a Facial Fracture

Cutis. 2017 September;100(3):E20-E23

References

Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964;76:349-356.
Whittle CH, Back GA, Champion RH. Recurrent neutrophilic dermatosis of the face—a variant of Sweet’s syndrome. Br J Dermatol. 1968;80:806-810.
Von den Driesch P. Sweet’s syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31:535-536.
Honigsmann H, Cohen PR, Wolff K. Acute febrile neutrophilic dermatosis (Sweet’s syndrome). Wien Klin Wochenschr. 1979;91:842-847.
Limdiwala PG, Parikh SJ, Shah JS. Sweet’s Syndrome. Indian J Dent Res. 2014;25:401-405.
Walling HW, Snipes CJ, Gerami P, et al. The relationship between neutrophilic dermatosis of the dorsal hands and sweet syndrome: report of 9 cases and comparison to atypical pyoderma gangrenosum. Arch Dermatol. 2006;142:57-63.
Ratzinger G, Burgdorf W, Zelger BG, et al. Acute febrile neutrophilic dermatosis: a histopathologic study of 31 cases with review of literature. Am J Dermatopathol. 2007;29:125-133.
Moschella SL, Davis MDP. Neutrophilic dermatoses. In: Bolognia J, Jorizzo J, Rapini R, eds. Dermatology. 2nd ed. Philadelphia, PA: Elsevier; 2012:423-428.
Fett DL, Gibson LE, Su WP. Sweet’s syndrome: signs and symptoms and associated disorders. Mayo Clinic Proc. 1995;70:234-240.
Carvalho R, Fernandes C, Afonso A, et al. Drug-induced Sweet’s syndrome by alclofenac. Cutan Ocul Toxicol. 2011;30:315-316.
Moghimi J, Pahlevan D, Azizzadeh M, et al. Isotretinoin-associated Sweet’s syndrome: a case report. Daru. 2014;22:69.
Cholongitas E, Pipili C, Dasenaki M, et al. Piperacillin/tazobactam-induced Sweet syndrome in a patient with chronic lymphocytic leukemia and autoimmune cholangitis. Am J Dermatopathol. 2008;30:203-204.
Kandula S, Burke WS, Goldfarb JN. Clindamycin-induced Sweet syndrome. J Am Acad Dermatol. 2010;62:898-900.
Jamet A, Lagarce L, Le Clec’h C, et al. Doxycycline-induced Sweet’s syndrome. Eur J Dermatol. 2008;18:595-596.
Cartee TV, Chen SC. Sweet syndrome associated with hydralazine-induced lupus erythematosus. Cutis. 2012;89:121-124.
Baybay H, Elhatimi A, Idrissi R, et al. Sweet’s syndrome following oral ciprofloxacin therapy. Ann Dermatol Venereol. 2011;138:606-607.
Khaled A, Kharfi M, Fazaa B, et al. A first case of trimethoprim-sulfamethoxazole induced Sweet’s syndrome in a child. Pediatr Dermatol. 2009;26:744-746.
Calixto R, Menezes Y, Ostronoff M, et al. Favorable outcome of severe, extensive, granulocyte colony-stimulating factor-induced, corticosteroid-resistant Sweet’s syndrome treated with high-dose intravenous immunoglobulin. J Clin Oncol. 2014;32:E1-E2.
Margaretten ME, Ruben BS, Fye K. Systemic sulfa-induced Sweet’s syndrome. Arthritis Rheum. 2008;59:1044-1046.
Tanguy-Schmidt A, Avenel-Audran M, Croué A, et al. Bortezomib-induced acute neutrophilic dermatosis. Ann Dermatol Venereol. 2009;136:443-446.
Choonhakarn C, Chaowattanapanit S. Azathioprine-induced Sweet’s syndrome and published work review. J Dermatol. 2013;40:267-271.
Cyrus N, Stavert R, Mason AR, et al. Neutrophilic dermatosis after azathioprine exposure. JAMA Dermatol. 2013;149:592-597.
Hurtado-Garcia R, Escribano-Stablé JC, Pascual JC, et al. Neutrophilic dermatosis caused by azathioprine hypersensitivity. Int J Dermatol. 2012;51:1522-1525.
Valentine MC, Walsh JS. Neutrophilic dermatosis caused by azathioprine. Skinmed. 2011;9:386-388.
Kim JS, Roh HS, Lee JW, et al. Distinct variant of Sweet’s syndrome: bortezomib-induced histiocytoid Sweet’s syndrome in a patient with multiple myeloma. Int J Dermatol. 2012;51:1491-1493.
Ozlem C, Deram B, Mustafa S, et al. Propylthiouracil-induced anti-neutrophil cytoplasmic antibodies and agranulocytosis together with granulocyte colony-stimulating factor induced Sweet’s syndrome in a patient with Graves’ disease. Intern Med. 2011;50:1973-1976.
Kyllo RL, Parker MK, Rosman I, et al. Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol. 2014;70:E85-E86.
Pintova S, Sidhu H, Friedlander PA, et al. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013;23:498-501.
Yorio JT, Mays SR, Ciurea AM, et al. Case of vemurafenib-induced Sweet’s syndrome. J Dermatol. 2014;41:817-820.
Pattanaprichakul P, Tetzlaff MT, Lapolla WJ, et al. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol. 2014;41:326-328.
Trickett HB, Cumpston A, Craig M. Azacitidine-associated Sweet’s syndrome. Am J Health Syst Pharm. 2012;69:869-871.
Tintle S, Patel V, Ruskin A, et al. Azacitidine: a new medication associated with Sweet syndrome. J Am Acad Dermatol. 2011;64:E77-E79.
Thieu KP, Rosenbach M, Xu X, et al. Neutrophilic dermatosis complicating lenalidomide therapy. J Am Acad Dermatol. 2009;61:709-710.
Dickson EL, Bakhru A, Chan MP. Topotecan-induced Sweet’s syndrome: a case report. Gynecol Oncol Case Rep. 2013;4:50-52.
Kümpfel T, Gerdes LA, Flaig M, et al. Drug-induced Sweet’s syndrome after mitoxantrone therapy in a patient with multiple sclerosis. Mult Scler. 2011;17:495-497.
Martorell-Calatayud A, Requena C, Sanmartin O, et al. Gemcitabine-associated sweet syndrome-like eruption. J Am Acad Dermatol. 2011;65:1236-1238.
Pang A, Tan KB, Aw D, et al. A case of Sweet’s syndrome due to 5-azacytidine and vorinostat in a patient with NK/T cell lymphoma. Cutan Ocul Toxicol. 2012;31:64-66.
El Moutaoui L, Zouhair K, Benchikhi H. Sweet syndrome induced by chloroquine. Ann Dermatol Venereol. 2009;136:56-57.
Rosmaninho A, Lobo I, Selores M. Sweet’s syndrome associated with the intake of a selective cyclooxygenase-2 (COX-2) inhibitor. Cutan Ocul Toxicol. 2011;30:298-301.
Alencar C, Abramowtiz M, Parekh S, et al. Atypical presentations of Sweet’s syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. Am J Hematol. 2009;84:688-689.
Keidel S, McColl A, Edmonds S. Sweet’s syndrome after adalimumab therapy for refractory relapsing polychondritis. BMJ Case Rep. 2011;2011.
Rondina A, Watson AC. Bullous Sweet’s syndrome and pseudolymphoma precipitated by IL-2 therapy. Cutis. 2010;85:206-213.
Gheorghe L, Cotruta B, Trifu V, et al. Drug-induced Sweet’s syndrome secondary to hepatitis C antiviral therapy. Int J Dermatol. 2008;47:957-959.
Zobniw CM, Saad SA, Kostoff D, et al. Bortezomib-induced Sweet’s syndrome confirmed by rechallenge. Pharmacotherapy. 2014;34:E18-E21.
Kolb-Mäurer A, Kneitz H, Goebeler M. Sweet-like syndrome induced by bortezomib. J Dtsch Dermatol Ges. 2013;11:1200-1202.
Thuillier D, Lenglet A, Chaby G, et al. Bortezomib-induced eruption: Sweet syndrome? two case reports [in French]. Ann Dermatol Venereol. 2009;136:427-430.
Kim MJ, Jang KT, Choe YH. Azathioprine hypersensitivity presenting as sweet syndrome in a child with ulcerative colitis. Indian Pediatr. 2011;48:969-971.
Truchuelo M, Bagazgoitia L, Alcántara J, et al. Sweet-like lesions induced by bortezomib: a review of the literature and a report of 2 cases. Actas Dermosifiliogr. 2012;103:829-831.
Hoelt P, Fattouh K, Villani AP. Dermpath & clinic: drug-induced Sweet syndrome. Eur J Dermatol. 2016;26:641-642.
Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet’s syndrome. J Am Acad Dermatol. 1996;34:918-923.
Thompson DF, Montarella KE. Drug-induced Sweet’s syndrome. Ann Pharmacother. 2007;41:802-811.

Comment

Although SS itself is relatively rare, there has been an increasing incidence of the drug-induced subtype, most often in association with use of granulocyte colony-stimulating factor and granulocyte monocyte-stimulating factor. There also have been reported associations with a growing number of medications that include antibiotics, antiepileptic drugs, furosemide, hydralazine, and all-trans retinoic acid.^11-19 Moghimi et al¹¹ also reported an association with antivirals, cancer biotherapies, nonsteroidal anti-inflammatory drugs, psychotropes, azathioprine, oral contraceptives, and propylthiouracil.^10,20-26 Moghimi et al¹¹ further reported an association with several vaccines.

Several therapies for advanced melanoma also have been reviewed in the literature, including ipilimumab and vemurafenib,^27-30 as have several medications for the treatment of myelodysplastic syndrome including azacitidine.^31,32 A severe episode of drug-induced SS, predominantly on the legs, has been reported in association with lenalidomide, an immunomodulatory agent used in the treatment of myelodysplastic syndrome.³³

Additional medications more recently involved in the pathogenesis of drug-induced SS include the chemotherapeutic agents topetecan, mitoxantrone, gemcitabine, and vorinostat.^34-37 The antimalarial medication chloroquine also has been implicated, as have selective cyclooxygenase-2 inhibitors, hypomethylating agents, the tumor necrosis factor inhibitor adalimumab, IL-2 therapies, aripiprazole, and several other medications.^38-49

Despite drug-induced SS being reported in association with an increasing number of medications, there had been a lack of appropriate diagnostic criteria. To that end, Walker and Cohen⁵⁰ proposed 5 specific diagnostic criteria in 1996, including abrupt onset of painful erythematous plaques or nodules, histopathologic evidence of a dense neutrophilic infiltrate without evidence of leukocytoclastic vasculitis, pyrexia (temperature >38°C), temporal relationship between drug ingestion and clinical presentation or temporally related recurrence after oral rechallenge, and temporally related resolution of lesions after drug withdrawal or treatment with systemic corticosteroids.^50,51 Our patient met all of these criteria.

Conclusion

The number of cases of drug-induced SS in the literature continues to climb; however, the association with acetaminophen-codeine is unique. The importance of this case lies in educating both physicians and pharmacists alike regarding a newly recognized adverse effect of acetaminophen-codeine. Because acetaminophen-codeine often is used for its analgesic properties, and the predominant symptom of the cutaneous eruption of SS is pain, the therapeutic value of acetaminophen-codeine is substantially diminished in acetaminophen-codeine–induced SS. Accordingly, in these cases, the medication may be discontinued or substituted upon recognition of this adverse reaction to reduce patient morbidity.

Sweet Syndrome Induced by Oral Acetaminophen-Codeine Following Repair of a Facial Fracture

References

Comment

Conclusion

Pages

Recommended Reading